REFERENCES
2. Farinelli L, Riccio M, Gigante A, De Francesco F. Pain management strategies in osteoarthritis. Biomedicines. 2024;12:805.
3. Kim EH, Jeon S, Park J, et al. Progressing future osteoarthritis treatment toward precision medicine: integrating regenerative medicine, gene therapy and circadian biology. Exp Mol Med. 2025;57:1133-42.
4. Zhang H, Felthaus O, Prantl L. Adipose tissue-derived therapies for osteoarthritis: multifaceted mechanisms and clinical prospects. Cells. 2025;14:669.
5. Kim GB, Seo MS, Park WT, Lee GW. Bone marrow aspirate concentrate: its uses in osteoarthritis. Int J Mol Sci. 2020;21:3224.
6. Forbes J, Jackson GR, Knapik DM, et al. The use of amniotic tissue-derived products in orthopedic surgery: a narrative review. Injury. 2024;55:111901.
7. Sanz-Nogués C, O’Brien T. Current good manufacturing practice considerations for mesenchymal stromal cells as therapeutic agents. Biomater Biosyst. 2021;2:100018.
8. Di Matteo B, Vandenbulcke F, Vitale ND, et al. Minimally manipulated mesenchymal stem cells for the treatment of knee osteoarthritis: a systematic review of clinical evidence. Stem Cells Int. 2019;2019:1735242.
9. Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med. 2017;6:1445-51.
10. Asgarpour K, Shojaei Z, Amiri F, et al. Exosomal microRNAs derived from mesenchymal stem cells: cell-to-cell messages. Cell Commun Signal. 2020;18:149.
11. Shimomura K, Wong KL, Saseendar S, et al. Exploring the potential of mesenchymal stem/stromal cell-derived extracellular vesicles as cell-free therapy for osteoarthritis: a narrative review. J Cartil Jt Preserv. 2024;4:100184.
12. Turlo AJ, Hammond DE, Ramsbottom KA, et al. Mesenchymal stromal cell secretome is affected by tissue source and donor age. Stem Cells. 2023;41:1047-59.
13. Dubey NK, Mishra VK, Dubey R, Deng YH, Tsai FC, Deng WP. Revisiting the advances in isolation, characterization and secretome of adipose-derived stromal/stem cells. Int J Mol Sci. 2018;19:2200.
14. Trzyna A, Banaś-Ząbczyk A. Adipose-derived stem cells secretome and its potential application in “stem cell-free therapy”. Biomolecules. 2021;11:878.
15. Kehl D, Generali M, Mallone A, et al. Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential. NPJ Regen Med. 2019;4:8.
16. Zhuang J, Hang R, Sun R, et al. Multifunctional exosomes derived from bone marrow stem cells for fulfilled osseointegration. Front Chem. 2022;10:984131.
17. Ragni E, Papait A, Perucca Orfei C, et al. Amniotic membrane-mesenchymal stromal cells secreted factors and extracellular vesicle-miRNAs: anti-inflammatory and regenerative features for musculoskeletal tissues. Stem Cells Transl Med. 2021;10:1044-62.
18. Muntiu A, Papait A, Vincenzoni F, et al. Disclosing the molecular profile of the human amniotic mesenchymal stromal cell secretome by filter-aided sample preparation proteomic characterization. Stem Cell Res Ther. 2023;14:339.
19. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211-28.
20. Giordano R, Canesi M, Isalberti M, et al. Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study. J Transl Med. 2014;12:14.
21. Papait A, Ragni E, Cargnoni A, et al. Comparison of EV-free fraction, EVs, and total secretome of amniotic mesenchymal stromal cells for their immunomodulatory potential: a translational perspective. Front Immunol. 2022;13:960909.
22. Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638-46.
23. Cavalleri T, Angelici L, Favero C, et al. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease. PLoS One. 2017;12:e0176680.
24. D’haene B, Mestdagh P, Hellemans J, Vandesompele J. miRNA expression profiling: from reference genes to global mean normalization. Methods Mol Biol. 2012;822:261-72.
25. Aparicio-Puerta E, Hirsch P, Schmartz GP, Kern F, Fehlmann T, Keller A. miEAA 2023: updates, new functional microRNA sets and improved enrichment visualizations. Nucleic Acids Res. 2023;51:W319-25.
26. Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 2015;43:W566-70.
27. Iulian Stanciugelu S, Homorogan C, Selaru C, et al. Osteoarthritis and microRNAs: do they provide novel insights into the pathophysiology of this degenerative disorder? Life. 2022;12:1914.
28. Endisha H, Rockel J, Jurisica I, Kapoor M. The complex landscape of microRNAs in articular cartilage: biology, pathology, and therapeutic targets. JCI Insight. 2018;3:e121630.
29. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
31. Wang W, Rigueur D, Lyons KM. TGFβ signaling in cartilage development and maintenance. Birth Defects Res C Embryo Today. 2014;102:37-51.
32. Fan W, Li J, Wang Y, et al. CD105 promotes chondrogenesis of synovium-derived mesenchymal stem cells through Smad2 signaling. Biochem Biophys Res Commun. 2016;474:338-44.
33. Chang CB, Han SA, Kim EM, Lee S, Seong SC, Lee MC. Chondrogenic potentials of human synovium-derived cells sorted by specific surface markers. Osteoarthritis Cartilage. 2013;21:190-9.
34. Wu CC, Liu FL, Sytwu HK, Tsai CY, Chang DM. CD146+ mesenchymal stem cells display greater therapeutic potential than CD146- cells for treating collagen-induced arthritis in mice. Stem Cell Res Ther. 2016;7:23.
35. Li X, Guo W, Zha K, et al. Enrichment of CD146+ adipose-derived stem cells in combination with articular cartilage extracellular matrix scaffold promotes cartilage regeneration. Theranostics. 2019;9:5105-21.
36. Mukherjee A, Das B. The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis. Biomater Biosyst. 2024;13:100090.
37. Wilkinson DJ. Serpins in cartilage and osteoarthritis: what do we know? Biochem Soc Trans. 2021;49:1013-26.
38. Ripmeester EGJ, Caron MMJ, van den Akker GGH, et al. BMP7 reduces the fibrocartilage chondrocyte phenotype. Sci Rep. 2021;11:19663.
39. Saraiva M, Vieira P, O’Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020;217:e20190418.
40. Al-Qahtani AA, Alhamlan FS, Al-Qahtani AA. Pro-inflammatory and anti-inflammatory interleukins in infectious diseases: a comprehensive review. Trop Med Infect Dis. 2024;9:13.
41. van Helvoort EM, van der Heijden E, van Roon JAG, Eijkelkamp N, Mastbergen SC. The role of interleukin-4 and interleukin-10 in osteoarthritic joint disease: a systematic narrative review. Cartilage. 2022;13:19476035221098167.
42. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323-40.
43. Jayasuriya CT, Hu N, Li J, et al. Molecular characterization of mesenchymal stem cells in human osteoarthritis cartilage reveals contribution to the OA phenotype. Sci Rep. 2018;8:7044.
44. Zhang Y, Liu D, Vithran DTA, Kwabena BR, Xiao W, Li Y. CC chemokines and receptors in osteoarthritis: new insights and potential targets. Arthritis Res Ther. 2023;25:113.
45. Reboul P, Guévremont M, Martel-Pelletier J, et al. Hepatocyte growth factor in osteoarthritis: when bone and cartilage decide to have a chat. Arthritis Res Ther. 2003;5:162.
46. Bollmann M, Lokau J, Garbers C, Bertrand J. Interleukin-11 - a new cytokine in osteoarthritis? Osteoarthritis and Cartilage. 2022;30:S168-9.
47. Kohrs L, Buettner FFR, Lokau J, Garbers C. The biology of interleukin-6 family cytokines is regulated by glycosylation. Biochem J. 2025;482:535-51.
48. Yan D, Kc R, Chen D, Xiao G, Im HJ. Bovine lactoferricin-induced anti-inflammation is, in part, via up-regulation of interleukin-11 by secondary activation of STAT3 in human articular cartilage. J Biol Chem. 2013;288:31655-69.
49. Yang T, Li C, Li Y, et al. MicroRNA-146a-5p alleviates the pathogenesis of osteoarthritis by inhibiting SDF-1/CXCR4-induced chondrocyte autophagy. Int Immunopharmacol. 2023;117:109938.
50. Qin H, Wang C, He Y, et al. Silencing miR-146a-5p protects against injury-induced osteoarthritis in mice. Biomolecules. 2023;13:123.
51. Zhang X, Wang C, Zhao J, et al. miR-146a facilitates osteoarthritis by regulating cartilage homeostasis via targeting Camk2d and Ppp3r2. Cell Death Dis. 2017;8:e2734.
52. Zhang H, Zheng W, Li D, Zheng J. miR-146a-5p promotes chondrocyte apoptosis and inhibits autophagy of osteoarthritis by targeting NUMB. Cartilage. 2021;13:1467S-77.
53. Xu J, Qian X, Ding R. MiR-24-3p attenuates IL-1β-induced chondrocyte injury associated with osteoarthritis by targeting BCL2L12. J Orthop Surg Res. 2021;16:371.
54. Philipot D, Guérit D, Platano D, et al. p16INK4a and its regulator miR-24 link senescence and chondrocyte terminal differentiation-associated matrix remodeling in osteoarthritis. Arthritis Res Ther. 2014;16:R58.
55. Rasheed Z, Rasheed N, Abdulmonem WA, Khan MI. MicroRNA-125b-5p regulates IL-1β induced inflammatory genes via targeting TRAF6-mediated MAPKs and NF-κB signaling in human osteoarthritic chondrocytes. Sci Rep. 2019;9:6882.
56. Li J, Zhao Z, Chen K, et al. Upregulation of miR-125b-5p relieves chondrocyte inflammation and apoptosis in osteoarthritis by repressing the YAP1/NF-κB pathway. aging. 2021;13.
57. Song J, Jin EH, Kim D, Kim KY, Chun CH, Jin EJ. MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis. BBA Clin. 2015;3:79-89.
58. Stadnik PS, Gilbert SJ, Tarn J, et al. Regulation of microRNA-221, -222, -21 and -27 in articular cartilage subjected to abnormal compressive forces. J Physiol. 2021;599:143-55.
59. Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. F1000Res. 2019;8:934.
60. Alahdal M, Duan L, Ouyang H, Wang D. The role of indoleamine 2,3 dioxygenase 1 in the osteoarthritis. Am J Transl Res. 2020;12:2322-43.
